Anti-viral properties of antipsychotic medications in the time of COVID-19.
作者信息
Girgis Ragy R, Lieberman Jeffrey A
机构信息
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Unit 31, New York, NY 10032, United States.
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and New York State Psychiatric Institute, 1051 Riverside Drive, Unit 31, New York, NY 10032, United States.
出版信息
Psychiatry Res. 2021 Jan;295:113626. doi: 10.1016/j.psychres.2020.113626. Epub 2020 Nov 30.
Abstract
摘要
相似文献
1
Anti-viral properties of antipsychotic medications in the time of COVID-19.新冠疫情期间抗精神病药物的抗病毒特性
Psychiatry Res. 2021 Jan;295:113626. doi: 10.1016/j.psychres.2020.113626. Epub 2020 Nov 30.
2
Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.为何 COVID-19 患者的哮喘发病率较低，这证明了将 EDTA 溶液重新用于预防和治疗 COVID-19 疾病是合理的。
Med Hypotheses. 2020 Nov;144:110027. doi: 10.1016/j.mehy.2020.110027. Epub 2020 Jun 26.
3
Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation.将一种临床使用的抗人乳头瘤病毒（HPV）药物重新开发为一种鼻内制剂，用于预防和治疗新型冠状病毒（SARS-CoV-2）感染。
Signal Transduct Target Ther. 2021 Aug 26;6(1):318. doi: 10.1038/s41392-021-00737-7.
4
Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.靶向 COVID-19 固有免疫反应的枢纽基因和通路：网络生物学视角。
Int J Biol Macromol. 2020 Nov 15;163:1-8. doi: 10.1016/j.ijbiomac.2020.06.228. Epub 2020 Jun 26.
5
COVID-19: Small-Molecule Clinical Trials Landscape.新冠病毒病（COVID-19）：小分子药物临床试验全景
Curr Top Med Chem. 2020;20(18):1577-1580. doi: 10.2174/156802662018200703154334.
6
Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.药物重新利用研究确定了潜在的新冠病毒抗病毒药物。
JAMA. 2020 Sep 8;324(10):928. doi: 10.1001/jama.2020.15948.
7
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?基于宿主的治疗药物用于治疗2019冠状病毒病（COVID-19）：抗病毒机制与抗癌机制之间的联系？
Int J Antimicrob Agents. 2020 Sep;56(3):106125. doi: 10.1016/j.ijantimicag.2020.106125. Epub 2020 Jul 30.
8
Psychiatry and COVID-19: The Role of Chlorpromazine.精神病学与新冠病毒-19：氯丙嗪的作用
Can J Psychiatry. 2020 Oct;65(10):739-740. doi: 10.1177/0706743720934997. Epub 2020 Jun 15.
9
Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses.几种美国食品药品监督管理局（FDA）批准的吩噻嗪类抗精神病药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和其他冠状病毒抗病毒作用的趋同证据。
Braz J Psychiatry. 2021 Sep-Oct;43(5):462-464. doi: 10.1590/1516-4446-2020-0024.
10
Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.重新利用药物对抗 SARS-CoV-2 的主蛋白酶：基于机制的见解，得到了现有实验室和临床数据的支持。
Mol Omics. 2020 Oct 1;16(5):474-491. doi: 10.1039/d0mo00057d. Epub 2020 Jul 22.
引用本文的文献
1
Six Decades of Dopamine Hypothesis: Is Aryl Hydrocarbon Receptor the New D2?多巴胺假说的六十年：芳烃受体是新的D2受体吗？
Reports (MDPI). 2023 Aug 1;6(3):36. doi: 10.3390/reports6030036.
2
Outpatient Antipsychotic Use and Severe COVID-19: Avoiding the Impact of Age in a Real-World Data Study.门诊抗精神病药使用与严重 COVID-19：在真实世界数据研究中避免年龄的影响。
Int J Neuropsychopharmacol. 2024 Apr 1;27(4). doi: 10.1093/ijnp/pyae020.
3
Post-COVID condition: dispensation of drugs and diagnostic tests as proxies of healthcare impact.新冠后状况：药物和诊断测试的配给作为医疗保健影响的替代指标。
Intern Emerg Med. 2023 Apr;18(3):801-809. doi: 10.1007/s11739-023-03228-5. Epub 2023 Mar 21.
4
Bromodomains in Human-Immunodeficiency Virus-Associated Neurocognitive Disorders: A Model of Ferroptosis-Induced Neurodegeneration.人类免疫缺陷病毒相关神经认知障碍中的溴结构域：铁死亡诱导神经退行性变的模型
Front Neurosci. 2022 May 12;16:904816. doi: 10.3389/fnins.2022.904816. eCollection 2022.
本文引用的文献
1
Repurposing chlorpromazine to treat COVID-19: The reCoVery study.氯丙嗪治疗 COVID-19 的再利用：reCoVery 研究。
Encephale. 2020 Jun;46(3):169-172. doi: 10.1016/j.encep.2020.05.006. Epub 2020 May 16.
2
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.一种 SARS-CoV-2 蛋白相互作用图谱揭示了药物再利用的靶标。
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
3
MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells.中东呼吸综合征冠状病毒发病机制及已上市药物在人源单核细胞来源抗原提呈细胞中的抗病毒效果。
PLoS One. 2018 Mar 22;13(3):e0194868. doi: 10.1371/journal.pone.0194868. eCollection 2018.
4
Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.将临床已开发药物重新用于治疗中东呼吸综合征冠状病毒感染。
Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. doi: 10.1128/AAC.03036-14. Epub 2014 May 19.
5
Search for inhibitors of endocytosis: Intended specificity and unintended consequences.寻找内吞作用抑制剂：预期特异性和非预期后果。
Cell Logist. 2012 Oct 1;2(4):203-208. doi: 10.4161/cl.23967.
6
Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted.严重急性呼吸综合征冠状病毒通过网格蛋白依赖途径进入细胞质尾缺失的表达血管紧张素转换酶2的靶细胞。
J Virol. 2007 Aug;81(16):8722-9. doi: 10.1128/JVI.00253-07. Epub 2007 May 23.
Zotero 插件